A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Part of paid clinical trials in Miami, Florida.

Sponsor
Exelixis
Study ID
NCT07428616
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Meningioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Administered as specified in the treatment arm.

Study Details

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Key Dates

Start date
May 31, 2026
Status verified
May 2026
Primary completion
Feb 29, 2028
Completion
Sep 30, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zanzalintinib
    Participants will receive zanzalintinib once daily (QD).

Primary Outcome Measure

Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 12 months ]

Central Contacts

  • Exelixis Clinical Trials
    1-888-EXELIXIS (888-393-5494)
    [email protected]
  • Backup or International
    650-837-7400

Locations (3)

FacilityCityStateZIPSite coordinators
Exelixis Site #3MiamiFlorida33176-
Exelixis Site #2HoustonTexas77030-
Exelixis Site #1San AntonioTexas78229-

Find similar trials in Miami, FL

By research site
Exelixis· Miami, FLExelixis· Houston, TXExelixis· San Antonio, TX

Related Studies